Remicade: New Warnings, New Benefits
by Mary Anne Dunkin

Recent months have brought both good and bad news concerning the biologic agent infliximab (Remicade). 

The good news is that Remicade has shown increasing promise as a treatment for psoriasis. In a recent study, Remicade rapidly and significantly improved the signs and symptoms of severe plaque psoriasis. A separate study of those who did not respond to other therapies showed symptoms and skin lesions improved in the majority of patients receiving Remicade. 

Additionally, a small study showed Remicade eased symptoms of sarcoidosis -- an inflammatory condition in which lumps called granulomas form from blood vessels, cells and connective tissues. In still another study, Remicade produced improvements in patients with rheumatoid arthritis (RA) who showed no response to corticosteroids or DMARDs. 

But as the journals were reporting new-found benefits, Remicade's manufacturer, Centocor, was warning doctors of potentially dangerous adverse effects: an increased risk of lymphoma (cancer of the lymphatic system) and possible reductions in red and white blood cells, granulocytes and platelet counts, which could "confuse" immune system responses and lead to blood vessels that swell and then decay. 

The bottom line: If you get infusions of the biologic infliximab (Remicade) and experience symptoms such as fevers, night sweats, pale skin, easy bruising or swollen (but painless) lymph nodes -- which could be symptoms of lymphoma or another serious problem -- consult your doctor.